한글목차

세계 심부전 치료제 시장의 미래는 병원 약국, 소매 약국, 온라인 약국 시장에 기회가 있고 유망합니다. 세계 심부전 치료제 시장은 2025-2031년 12.5%의 연평균 복합 성장률(CAGR)로, 2031년까지 약 193억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 심혈관 질환 증가, 심혈관 질환 관련 연구 개발 활동에 대한 수요 증가, 고령화 인구 증가입니다.

• Lucintel의 예측에 따르면, 약물 유형별로 보면, 에이스 억제제는 혈관을 수축시키는 안지오텐신 생성을 막는 데 도움이 되고, 베타 차단제는 특정 화학 물질의 작용을 억제하기 때문에 계속해서 가장 큰 부문이 될 것으로 예상됩니다.
• 유통 채널별로는 특히 장기적인 지원이 필요한 홈케어 환경에서 심장질환 처방약 관리가 용이하다는 점에서 소매 약국이 가장 큰 비중을 차지할 것으로 보입니다.
• 지역별로는 북미가 심부전 환자 증가와 노인 인구 증가로 인해 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.

심부전 치료제 시장의 전략적 성장 기회

심부전 치료제의 전략적 성장 기회는 연구, 기술 및 환자 육성 결과입니다. 시장에서의 이러한 기회는 환자 치료 스펙트럼의 확대, 나아가 환자 회복 과정의 가능성을 보여줍니다.

• 개인맞춤형 의료의 발전: 개인맞춤형 의료 시장은 환자 고유의 특성에 맞게 치료를 맞춤화할 수 있는 능력으로 인해 괄목할 만한 성장이 예상됩니다. 유전자 연구와 바이오마커 연구는 개발된 치료법이 질병의 특정 경로에 초점을 맞출 수 있을 정도로 발전하고 있으며, 그 결과 환자들에게 보다 효과적인 치료법을 제공할 수 있게 되었습니다.
• 디지털 헬스 솔루션의 통합: 심부전 환자를 돌보는 새로운 방법으로 원격 환자 모니터링 및 장치와 같은 디지털 헬스 솔루션을 도입하여 발전할 수 있는 기회가 있습니다. 이 기술을 통해 발생 시점에 사용 가능한 데이터를 수집하고 필요에 따라 치료를 변경할 수 있어 환자의 순응도를 높이고 치료 결과를 개선할 수 있습니다.
• 신흥 시장 진출: 특히 아시아 및 라틴아메리카으로의 확장은 심부전 치료제 제조업체에게 큰 기회가 될 것입니다. 개발 및 헬스케어 측면에서 이 지역의 성장의 주요 요인은 이들 지역의 심부전 발병률 증가와 의료비 증가에 기인합니다.
• 구 치료영역 개발: 여러 약물을 조합하여 심부전의 다양한 측면을 표적화함으로써 치료 효과를 극대화할 수 있는 기회가 있습니다. 병용요법은 임상반응을 개선하고 입원을 예방할 수 있어 회사의 성장을 가속할 것으로 기대됩니다.
• 심장 보호 전략의 표적화: 심부전에 대한 심장 보호 전략의 표적화 또한 새로운 성장 기회를 창출할 수 있을 것입니다. 카테터 삽입 전 바이오마커 연구 및 기타 마일스톤과 같은 예방과 중재를 위한 모든 연구는 이 질환으로 인한 장애 부담을 줄이고 환자의 좋은 결과를 연장하는 데 도움이 될 것으로 보입니다.

이러한 시장 개발은 향후 심부전 치료제가 어떻게 개발되고, 더 나은 치료법, 더 나은 치료의 질, 더 넓은 시장으로 이어질 수 있는지를 정의하는 핵심 포인트가 되고 있습니다.

심부전 치료제 시장 성장 촉진요인 및 과제

심부전 치료제 시장은 시장 개발 및 채택을 연구하는 촉진요인과 과제 모두에 의해 특징지어집니다. 주요 촉진요인으로는 기술 발전, 심부전 인구 증가, 연구 자금 증가 등을 들 수 있습니다. 도전요인으로는 규제적 이슈, 높은 개발 비용, 시장 경쟁력 등을 들 수 있습니다. 변화하는 심부전 환경에서 효과적으로 길을 개척하기 위해서는 이러한 도전의 의미를 이해해야 합니다.

심부전 치료제 시장을 견인하는 요인은 다음과 같다:

• 기술 발전: 약물 및 전달 시스템 관련 기술 발전이 심부전 치료제의 성장을 가속하고 있습니다. 새로운 약물 계열, 약물 조합, 개선된 전달 시스템의 사용은 전반적인 치료 효과와 환자 예후를 개선하고 있습니다. 이는 또한 심부전 관리를 강화하고 새로운 치료법을 위한 길을 열어주고 있습니다.
• 심부전 유병률 증가: 이 역시 의약품 개발을 촉진하는 큰 요인으로 작용할 것으로 보입니다. 심부전 환자 증가는 보다 효과적인 신약 시장 기반을 확대합니다. 이러한 추세는 제약업계가 심부전 환자 증가에 대응하기 위해 연구개발에 더 많은 자원을 투입할 것을 촉구하고 있습니다.
• 연구 자금 증가: 주로 심부전 치료제 개발에 있어 민관 양측의 연구 자금이 증가하고 있습니다. 이를 통해 보다 광범위한 임상시험 실시, 새로운 치료법 검토, 특정 환자를 대상으로 한 치료법 개발이 가능해졌습니다. 이러한 자금 조달은 새로운 치료법을 시행하는 데 있어 매우 중요합니다.

심부전 치료제 시장의 과제는 다음과 같다:

• 규제 장벽: 심부전 치료제를 다루는 경우, 규제 장벽도 만만치 않습니다. 신약 승인에는 복잡한 법적 장벽과 관료적 구조가 있어 매우 번거롭고 비용이 많이 듭니다. 법을 준수하는 것은 신약과 관련된 위험을 피하고 신약 시장에 안정성을 가져오는 데 도움이 되기 때문에 매우 중요합니다.
• 높은 개발 비용: 제약업계는 부적절한 심부전 치료제 개발 비용에 큰 부담을 느끼고 있습니다. 임상시험뿐만 아니라 비임상시험, 의약품 개발, 상품화에도 많은 비용이 소요되기 때문에 새로운 치료법 개발에 대한 의욕을 잃게 됩니다. 이러한 비용을 효과적으로 관리하고, 유효성뿐만 아니라 안전성 요소도 함께 해결하는 것은 제약업계가 직면한 큰 딜레마입니다.
• 시장 경쟁: 심부전 치료제 시장에는 여러 가지 요인이 영향을 미치는데, 그 중 하나는 다수의 제약회사들 시장 경쟁입니다. 이러한 주장을 위해서는 이러한 치료법을 더욱 정교하게 만들고, 시장에서 강화될 수 있도록 높은 비용을 보장해야 합니다. 이러한 경쟁 압력은 신제품의 가격이나 새로운 치료법의 보급에도 영향을 미칠 수 있습니다.

일반적으로 이러한 촉진요인과 억제요인이 심부전 치료제 시장을 규정하며, 모든 새로운 치료법의 설계, 채택 및 시장 진입에 영향을 미칩니다. 이러한 요인들을 적절히 해결하는 것은 심부전 치료제의 발전뿐만 아니라 환자 예후를 개선하는 데에도 필수적입니다.

목차

제1장 주요 요약

제2장 세계의 심부전 치료제 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 심부전 치료제 시장 동향(2019-2024년)과 예측(2025-2031년)
• 약제 유형별
  • ACE 억제제
  • 안지오텐신 수용체 차단제
  • 베타 차단제
  • 이뇨제
  • 기타
• 용도별
  • 주사
  • 캡슐
  • 정제
• 최종 용도별
  • 병원
  • 전문센터
  • 기타
• 유통 채널별
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 지역별 : 세계의 심부전 치료제 시장
• 북미의 심부전 치료제 시장
• 유럽의 심부전 치료제 시장
• 아시아태평양의 심부전 치료제 시장
• 기타 지역의 심부전 치료제 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 약제 유형별
  • 용도별
  • 최종 용도별
  • 유통 채널별
  • 지역별
• 세계 심부전 치료제 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 심부전 치료제 시장 생산능력 확대
  • 세계 심부전 치료제 시장에서의 인수합병(M&A) 및 합작투자(JV)
  • 인증 및 라이선싱

제7장 주요 기업 개요

• Bayer
• Novartis
• Amgen
• Merck
• AstraZeneca
• Bristol-Myers Squibb
• Boehringer Ingelheim International
• Pfizer
• Johnson & Johnson Services
• Otsuka Pharmaceutical

영문목차

The future of the global heart failure drug market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global heart failure drug market is expected to reach an estimated $19.3 billion by 2031 with a CAGR of 12.5% from 2025 to 2031. The major drivers for this market are increasing cardiovascular diseases, rising demand for R&D activities related to cardiovascular diseases, and a growing aging population.

• Lucintel forecasts that, within the drug type category ace inhibitors segment will remain the largest segment because it helps in preventing the formation of angiotensin that results in blood vessels to constrict, and beta blockers block the action of certain chemicals.
• Within the distribution channel category, retail pharmacies will remain the largest segment due to ease at managing prescriber medications, especially for heart diseases in the homecare setting where long-term support is needed.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to the increasing prevalence of heart failure cases and geriatric population in the region.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Heart Failure Drug Market

Like every other market around, the heart failure drug market is characterized by a number of emerging trends which is bound to revolutionize treatment in the near future. It also points at the development of understanding of drug delivery and the field of personalized medicine as well as the new technologies assimilated.

• Targeting Personalized Medicine: A stand out trend in patients who struggle with heart failure is the emergence of personalized medicine. Advancement of genomic and biomarkers cancer treatment seeks to cure diseases by focusing on the individual patient. The goal of this method is to increase the efficacy and safety of treatment by choosing the medicines based on genetic and molecular characteristics.
• Use of Digital Technology: Incorporating monitoring devices like wearables and employing telemonitoring have facilitated better management of heart failure patients. These devices are essential in collecting the patient's data in real time thus allowing appropriate responses to be made or changes in the treatment made. It also helps in improving the compliance of patients and controlling efficiently attendees suffering from heart failure.
• Attempting Multiple Modalities: The adoption of combination therapies continues to gain traction in the management of heart failure. Utilization of different drug families such as the ARNI with the SGLT2 inhibitors and other drugs has been proved to be beneficial to lessen the number of rehospitalizations among patients. This is indicative of changing attitudes where the treatment of complex disease entails several lines of treatment.
• Advancements in Drug Delivery Systems: Adhering to the concept of systems-based drug discovery the heart failure treatment systems are evolving at a satisfying rate. Innovative extended-release formulations and targeted delivery systems have improved drug absorption barriers and adherence rates. These developments seek to narrow the therapeutic gap for the treatment regimes.
• Increased Awareness Regarding Early Intervention and Prevention: An increasing attention is given on early intervention and prevention in the case of heart failure. This is evident as studies are directed on determining early biomarkers and creating interventions that successfully stop the progression of heart failure. It emphasizes this shift toward management of disease rather than management of effects.

These trends are driving significant changes in the heart failure drug landscape which would result in better, more targeted, and technologically superior treatment options.

Recent Developments in the Heart Failure Drug Market

Recent advances in the field of heart failure drugs, show the increasing understanding of the disease and advancing in more treatment options. These new achievements reach out to new drug releases, new treatment approaches or new management techniques.

• Approval of Novel Drug Classes: According to current trends in heart failure treatment, novel drug classes, such as SGLT2 inhibitors as well as ARNI therapies, have been recently approved over the years. Drugs such as Farxiga and Entresto have been proven to efficiently alleviate [eliminate] heart failure's symptoms, reduce hospitalization, and even death which is new in the realm of therapies.
• Advances in Combination Therapy Research: Studies of combination therapies proved to be effective: certain combinations, like those using ARNI in conjunction with SGLT2 inhibitors, allowed obtaining better treatment effects than monotherapy. Such combination therapies are designed to target aspects of heart failure via multiple pathways in order to optimize the treatment's efficacy.
• Emergence of Personalized Treatment Strategies: Personalized treatment approaches are on the rise as recent technical breakthroughs in genomics and biomarker investigation allow more specific adjuvant treatments to be administered. Personalized medicine focuses on optimal disease management based on individual characteristics of patients rather than conventional chemotherapy.
• Development of Innovative Drug Delivery Systems: Advanced drug delivery systems are enhancing the administration and effectiveness of heart failure medications. Recent advancements in formulation and delivery technologies such as sustained-release formulations and targeted drug delivery systems are improving drug uptake and medication adherence.
• Expansion of Clinical Trials and Research: The expansion of clinical trials and research in heart failure is fueling the invention of new therapies and treatment approaches. Further research is being conducted on novel drugs, combinations of drugs, and technology with meaningful implications for heart failure and its treatment.

These changes introduce new therapies, improve the efficacy of the heart failure drug market, and boost research and clinical practices.

Strategic Growth Opportunities for Heart Failure Drug Market

The strategic growth opportunities in heart failure drugs are a consequence of research and technology, and patient nurturing. These opportunities in the market speak of possibilities of extending the treatment spectrum to patients and even the recovery processes for patients.

• Advancement in Personalized Medicine: The market for personalized medicine is expected to grow remarkably with the capacity to customize treatments to suit unique patient characteristics. Genetic and biomarker studies have advanced to the extent that therapies developed will focus on specific pathways of the disease thus providing more effective treatment methods for patients.
• Integration of Digital Health Solutions: There is an opportunity in evolving with new ways of looking after heart failure patients by including digital health solutions such as remote patient monitoring and devices. This technology collects data that is available as it happens and allows for treatment to be modified as needed, thereby increasing patient compliance and improving outcomes.
• Extending to Emerging Markets: Specifically, expanding to regions such as Asia and Latin America is a great chance to the heart failure drugs manufacturers. The primary factors of the growth of this area in both development and health care are the rising incidence of heart failure and enhancement of healthcare spending in these areas.
• Former Therapeutic Areas Development: There is an opportunity to maximize the efficacy of the treatment by creating a combination of several drugs and targeting various aspects of heart failure. Combination therapy improves clinical responses and prevents hospitalizations, and so it is expected to foster the company's growth.
• Targeting Cardioprotective Strategies: Targeting cardioprotective strategies to heart failure also must create new growth chances. All the research directed towards prevention and intervention including the performance of biomarker studies and other milestones undertaken before catheters, will help to decrease the total disability burden of the disease and enhance the length of positive outcomes in the patients.

These avenues of expansion are becoming the central point in defining how heart failure drugs will be developed in the future, leading to better therapies, better quality of care, and broader markets.

Heart Failure Drug Market Driver and Challenges

The heart failure drug market is characterized by both drivers and challenges that study its development and adoption. Key drivers include technological advancement, an increasing heart failure population, and a rise in research funding. Challenges consist of regulatory challenges, high costs of development, and market competitiveness. The meaning of these challenges needs to be understood so that one can effectively make their way in the changing environment of heart failure.

The factors responsible for driving the heart failure drug market include:

• Technological Advancement: Technological advancement as far as the drugs and their delivery systems is concerned is fostering the growth of drugs for heart failure disease. The use of new drug classes, combinations of drugs together with improved delivery systems are increasing the overall efficacy of treatments and patients' outcomes. This also enhances the management of heart failure and paves the way for new treatments.
• Increasing Prevalence of Heart Failure: This can also be seen as a major factor that drives drug development. The expanding heart failure patients add a wider market base for new and more effective drugs. This trend encourages pharmaceutical industries to put more resources into research and development so as to cope with the increase level of the disease.
• Increased Research Funding: Increased research funding is coming from both the public and private sector primarily in heart failure drug development. This makes it possible for the conduct of wider clinical trials, investigation of new treatment options, and development of therapies targeting specific patients. This financing is important for the progress of implementing new treatment.

Challenges in the heart failure drug market are:

• Regulatory Hurdles: Regulatory hurdles are also difficult when dealing with heart failure drugs. There are complex legal barriers and bureaucratic structures which are quite tedious and expensive in the approval of therapy for new drug entities. Following the law is crucial as it helps to avoid the risk associated with new drugs and also helps to bring stabiles in the market for new drugs.
• High Development Costs: The pharmaceutical industry is heavily burdened with the cost of developing new heart failure drugs which are inappropriate. High expenditure levels on clinical trials as well as the non-clinical exploratory studies, drug development, and commercialization make it discouraging to venture into the development of new therapies. The implications of managing these expenses effectively and addressing effectiveness as well as safety factors is a major dilemma that pharmaceutical industries face.
• Market Competition: Several factors will influence the heart failure drug market including the existing market competition among the numerous pharmaceutical firms. Such a claim requires a further refinement of these treatments and the assurance of high costs to ensure it is enhanced in the market. Such competitive pressures may dictate the price of new products and even the uptake of new therapies.

In general, these enablers and detractors define the heart failure drug market, impacting the design, uptake and market entry of any new therapies. If these factors are to be adequately addressed, it is vital to the progress of heart failure therapeutics as well as to the improvement of patient outcomes.

List of Heart Failure Drug Companies

Companies in the market compete based on product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies heart failure drug companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the heart failure drug companies profiled in this report include-

• Bayer
• Novartis
• Amgen
• Merck
• Astrazeneca
• Bristol-Myers Squibb
• Boehringer Ingelheim International
• Pfizer
• Johnson & Johnson Services
• Otsuka Pharmaceutical

Heart Failure Drug by Segment

The study includes a forecast for the global heart failure drug market by drug type, application, end use, distribution channel, and region.

Heart Failure Drug Market by Drug Type [Analysis by Value from 2019 to 2031]:

• Ace Inhibitors
• Angiotensin Receptor Blockers
• Beta Blockers
• Diuretics
• Others

Heart Failure Drug Market by Application [Analysis by Value from 2019 to 2031]:

• Injection
• Capsule
• Tablets

Heart Failure Drug Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Specialty Centers
• Others

Heart Failure Drug Market by Distribution Channel [Analysis by Value from 2019 to 2031]:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Heart Failure Drug Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Heart Failure Drug Market

The drug development for the treatment of heart failure is changing fast thanks to the newer insights into the disease aetiology as well as new therapy options. New achievements in the development of heart failure therapy in the USA, China, Germany, India, and Japan show that there is a worldwide inclination to treat heart failure effectively and individually. This combines the approvals of new pharmacological agents, new clinical study results and novel treatment approaches to create mechanisms of heart failure management that are more effective and efficient.

• United States: In the U.S., recent developments in heart failure drugs include the approval of novel therapies such as SGLT2 inhibitors and angiotensin receptor-neprilysin inhibitors (ARNIs). Farxiga and Entresto, among notable others, have been illustrated as the effective agents causing a reduction on the incidence rate of heart failure related hospital admission and even mortality of the patient with heart failure. There is also better funding in the U.S. aimed at the development of targeted therapies such as those based on genomic and biomarker strategies.
• China: It has been argued that China has made impressive progress toward the development of heart failure drugs, especially through the emergence of indigenous ones and partnering with western pharmaceutical companies. Other newer modalities like the novel beta-blockers and ACE inhibitors are also being fervently adopted. Research in China is also aimed at combining regular medicines with new drug therapies to increase the treatment options available to patients with heart failure.
• Germany: Regarding heart failure drugs and their clinical development, German medicine in particular is focused on the study of the possibilities of advanced treatment, including combination therapies and novel drug delivery systems. The country has experienced numerous new drug approvals and has been conducting active research in the area of gene therapy and regenerative medicine. German institutions are also focused on enhancing established therapies with additional efforts in drug mechanisms and patient's population classification.
• India: The global trend of increasing heart failure therapeutics being developed and produced at an acceptable price range, with the help of local pharma tidal waves and overseas synergy is being experienced too in India. Such trends include introductory sales of lower-price generics with principal active heart failure drugs and current research and therapies of new heart failure drugs. Moreover, the country is concentrating on improving the availability of treatment in rural regions to reduce inequalities in the management of heart failure.
• Japan: In the last few years, other than ARNI therapies, which have now advanced, there have been several other new heart failure drug launches including novel diuretics. In Japan, researchers are developing new techniques for treating problems such as the regeneration of normal functional cardiac tissue using stem cells. The aim is to incorporate such novel therapies into the utilized treatment regimen along with the management of the entire problem for better outcomes.

Features of the Global Heart Failure Drug Market

Market Size Estimates: Heart failure drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Heart failure drug market size by various segments, such as by drug type, application, end use, distribution channel, and region in terms of ($B).

Regional Analysis: Heart failure drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug types, applications, end uses, distribution channels, and regions for the heart failure drug market.

Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the heart failure drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the heart failure drug market by drug type (ace inhibitors, angiotensin receptor blockers, beta blockers, diuretics, and others), application (injection, capsule, and tablets), end use (hospitals, specialty centers, and others), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Heart Failure Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Heart Failure Drug Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Heart Failure Drug Market by Drug Type
  • 3.3.1: ACE Inhibitors
  • 3.3.2: Angiotensin Receptor Blockers
  • 3.3.3: Beta Blockers
  • 3.3.4: Diuretics
  • 3.3.5: Others
• 3.4: Global Heart Failure Drug Market by Application
  • 3.4.1: Injection
  • 3.4.2: Capsule
  • 3.4.3: Tablets
• 3.5: Global Heart Failure Drug Market by End Use
  • 3.5.1: Hospitals
  • 3.5.2: Specialty Centers
  • 3.5.3: Others
• 3.6: Global Heart Failure Drug Market by Distribution Channel
  • 3.6.1: Hospital Pharmacies
  • 3.6.2: Retail Pharmacies
  • 3.6.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Heart Failure Drug Market by Region
• 4.2: North American Heart Failure Drug Market
  • 4.2.1: North American Market by Drug Type: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Diuretics, and Others
  • 4.2.2: North American Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.3: European Heart Failure Drug Market
  • 4.3.1: European Market by Drug Type: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Diuretics, and Others
  • 4.3.2: European Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.4: APAC Heart Failure Drug Market
  • 4.4.1: APAC Market by Drug Type: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Diuretics, and Others
  • 4.4.2: APAC Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.5: ROW Heart Failure Drug Market
  • 4.5.1: ROW Market by Drug Type: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Diuretics, and Others
  • 4.5.2: ROW Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Heart Failure Drug Market by Drug Type
  • 6.1.2: Growth Opportunities for the Global Heart Failure Drug Market by Application
  • 6.1.3: Growth Opportunities for the Global Heart Failure Drug Market by End Use
  • 6.1.4: Growth Opportunities for the Global Heart Failure Drug Market by Distribution Channel
  • 6.1.5: Growth Opportunities for the Global Heart Failure Drug Market by Region
• 6.2: Emerging Trends in the Global Heart Failure Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Heart Failure Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Heart Failure Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Bayer
• 7.2: Novartis
• 7.3: Amgen
• 7.4: Merck
• 7.5: AstraZeneca
• 7.6: Bristol-Myers Squibb
• 7.7: Boehringer Ingelheim International
• 7.8: Pfizer
• 7.9: Johnson & Johnson Services
• 7.10: Otsuka Pharmaceutical